Boris Mayzler
Family Medicine · Stamford, CTNPI 1417038753
Payments from drug & device makers
Across 213 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$974
- AstraZeneca$948
- Takeda Pharmaceuticals U.S.A., Inc.$203
- Axsome Therapeutics, Inc.$185
- Scilex Pharmaceuticals Inc.$185
- Novo Nordisk$156
- plus $928 from 23 others
What the payments were for
- Food & beverage$3,579100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 65 | $974 |
| AstraZeneca | 48 | $948 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $203 |
| Axsome Therapeutics, Inc. | 9 | $185 |
| Scilex Pharmaceuticals Inc. | 14 | $185 |
| Novo Nordisk | 13 | $156 |
| Pfizer | 7 | $115 |
| Nestle Healthcare Nutrition Inc. | 4 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $78 |
| Boehringer Ingelheim | 3 | $61 |
| Astellas Pharma US Inc | 3 | $54 |
| Medtronic(2 entities) | 3 | $54 |
| Genentech USA, Inc. | 3 | $49 |
| Abbott | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $40 |
| Bayer | 2 | $38 |
| Lilly USA, LLC | 2 | $35 |
| Aimmune Therapeutics, Inc. | 2 | $35 |
| Novartis | 2 | $34 |
| Ironwood Pharmaceuticals, Inc | 2 | $33 |
| Azurity Pharmaceuticals, Inc. | 2 | $30 |
| Johnson & Johnson | 1 | $23 |
| Nabriva Therapeutics, PLC | 1 | $22 |
| GSK | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Amgen | 1 | $18 |
| Circassia Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
How this compares
$3,579 in reported general payments places this provider in the 85th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 77 | $75,107 |
| EliquisApixaban | 76 | $56,787 |
| JardianceEmpagliflozin | 43 | $50,727 |
| CreonLipase/Protease/Amylase | 43 | $49,611 |
| OzempicSemaglutide | 19 | $30,392 |
| LinzessLinaclotide | 35 | $25,809 |
| XareltoRivaroxaban | 34 | $23,821 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $21,936 |
| FarxigaDapagliflozin Propanediol | 14 | $20,268 |
| MyrbetriqMirabegron | 25 | $19,713 |
| ZenpepLipase/Protease/Amylase | 15 | $15,488 |
| TradjentaLinagliptin | 16 | $13,878 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $11,959 |
| SymbicortBudesonide/Formoterol Fumarate | 45 | $11,469 |
| TrulicityDulaglutide | 13 | $11,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $18 | $87,06690 claims |
| AbbVieCreon, Linzess, Synthroid | $974 | $79,254125 claims |
| Boehringer IngelheimJardiance, Tradjenta | $61 | $64,60659 claims |
| PfizerEliquis | $115 | $56,78776 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Nexium | $948 | $56,724105 claims |
| Novo NordiskOzempic | $156 | $30,39219 claims |
| Johnson & JohnsonXarelto | $23 | $23,82134 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $19,71325 claims |
| Aimmune Therapeutics, Inc.Zenpep | $35 | $15,48815 claims |
| Lilly USA, LLCTrulicity | $35 | $11,23813 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $203 | $9,83312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Stamford
- Debra GramlichStamford$292K
- Nicole NelsonStamford$19K
- Natasha FergusonStamford$7K
- Hadrian HolderNew Haven$213K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.